Please try another search
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company’s lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.
Name | Age | Since | Title |
---|---|---|---|
Steven R. Gannon | 62 | 2020 | Independent Director |
John F. Valliant | 53 | 2014 | Founder, CEO & Director |
Barbara G. Duncan | 58 | 2020 | Independent Chairperson of the Board |
Pablo J. Cagnoni | 60 | 2019 | Independent Director |
Philina Lee | 46 | 2021 | Independent Director |
Rosalyn Juergens | - | 2018 | Member of Advisory Board |
Oliver Sartor | - | 2018 | Member of Advisory Board |
Donald A. Bergstrom | 51 | 2021 | Independent Director |
Geoffrey I. Shapiro | - | 2018 | Member of Advisory Board |
Teresa Bitetti | 62 | 2023 | Independent Director |
David D. Meek | 61 | 2023 | Independent Director |
Jeremy Bender | 53 | 2023 | Independent Director |
Gillies O’Bryan-Tear | - | 2018 | Member of Advisory Board |
Deepak Khuntia | - | 2018 | Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review